ZMYM2 and myeloproliferative disorder: Earlier work examining two FGFR1-containing fusion proteins, BCR-FGFR1 and ZNF198-FGFR1, provided important insights into mechanisms of cancer progression; specifically, this work identified the importance of the phospholipase PLCγ1 binding site at Y766 in the ZNF198-FGFR1 fusion, and the importance of the small adapter protein Grb2 binding site at Y177 in BCR-FGFR1 for progression of myeloproliferative disease in murine models [10].